Market Research Logo

US Market Report for Nuclear Medicine Imaging 2016 - MedCore

US Market Report for Nuclear Medicine Imaging 2016 - MedCore

PET/CT systems will continue to represent the largest segment in the nuclear medicine system market throughout the forecast, primarily due to its significantly higher ASP. In contrast, SPECT scanners represented the smallest segment. SPECT/CT scanners are cannibalizing the SPECT market as they offer increase patient benefits, namely the ability to superimpose a SPECT scan over a CT scan, which allows the physician to obtain more information. Despite the higher rate of growth and larger sales volume, the SPECT/CT segment will not overtake the PET/CT segment in terms of market share throughout the forecast as a result of the high ASP commanded by PET/CT devices.The U.S. market for nuclear medicine imaging includes positron emission tomography/computed tomography (PET/CT), single photon emission computed tomography (SPECT) and single photon emission computed tomography/computed tomography (SPECT/CT). In 2015, PET/CT systems represented the largest segment of the overall market.


LIST OF FIGURES
LIST OF CHARTS
EXECUTIVE SUMMARY
U.S. MEDICAL IMAGING DEVICE MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE CODES INVESTIGATED
PROCEDURES INCLUDED
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
1.1 RESEARCH SCOPE
1.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
PRODUCT ASSESSMENT
2.1 PRODUCT PORTFOLIOS
2.1.1 Nuclear Medicine Imaging
2.1.1.1 PET/CT
2.1.1.2 SPECT
2.1.1.3 SPECT/CT Devices
2.2 CLINICAL TRIALS
2.2.1 Bayer
2.2.2 Bracco
2.2.3 Carestream Health
2.2.4 Fujifilm
2.2.5 GE Healthcare
2.2.6 Guerbet
2.2.7 Hologic
2.2.8 Lantheus Medical Imaging
2.2.9 Philips Healthcare
2.2.10 Siemens Healthcare
2.2.11 Toshiba Medical Systems
NUCLEAR MEDICINE IMAGING MARKET
3.1 MARKET OVERVIEW
3.2 MARKET ANALYSIS AND FORECAST
3.2.1 PET/CT Market
3.2.2 SPECT Market
3.2.3 SPECT/CT Market
3.3 DRIVERS AND LIMITERS
3.3.1 Market Drivers
3.3.2 Market Limiters
3.4 COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
APPENDIX: COMPANY PRESS RELEASES
List of Charts
Chart 1 1: Medical Imaging Device Market by Segment, U.S., 2012 – 2022
Chart 1 2: Medical Imaging Device Market Overview, U.S., 2012 & 2022
Chart 3 1: Nuclear Medicine Imaging Market by Segment, U.S., 2012 – 2022
Chart 3 2: Nuclear Medicine Imaging Market Breakdown, U.S., 2015
Chart 3 3: Nuclear Medicine Imaging Market Breakdown, U.S., 2022
Chart 3 4: PET/CT Market, U.S., 2012 – 2022
Chart 3 5: SPECT Market, U.S., 2012 – 2022
Chart 3 6: SPECT/CT Market, U.S., 2012 – 2022
Chart 3 7: Leading Competitors, Nuclear Medicine Imaging Market, U.S., 2015
List of Figures
Figure 1 1: Medical Imaging Device Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
Figure 1 2: Medical Imaging Device Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
Figure 1 3: Companies Researched in this Report, U.S., 2015 (1 of 2)
Figure 1 4: Companies Researched in this Report, U.S., 2015 (2 of 2)
Figure 1 5: Factors Impacting the Medical Imaging Device Market by Segment, U.S. (1 of 2)
Figure 1 6: Factors Impacting the Medical Imaging Device Market by Segment, U.S. (2 of 2)
Figure 1 7: Recent Events in the Medical Imaging Device Market, U.S., 2012 – 2015
Figure 1 8: Procedure Codes Investigated, U.S., 2015 (1 of 3)
Figure 1 9: Procedure Codes Investigated, U.S., 2015 (2 of 3)
Figure 1 10: Procedure Codes Investigated, U.S., 2015 (3 of 3)
Figure 1 11: Medical Imaging Procedures Covered, U.S., 2015 (1 of 4)
Figure 1 12: Medical Imaging Device Markets Covered, U.S., 2015 (1 of 3)
Figure 1 13: Medical Imaging Device Markets Covered, U.S., 2015 (2 of 3)
Figure 1 14: Medical Imaging Device Markets Covered, U.S., 2015 (3 of 3)
Figure 1 15: Key Report Updates
Figure 1 16: Version History
Figure 2 1: PET/CT Devices by Company
Figure 2 2: SPECT Devices by Company
Figure 2 3: SPECT/CT Devices by Company
Figure 2 4: Perfusion CT as a Predictor for Response to Antiangiogenic Therapy
Figure 2 5: A Multicenter Study of Iomeron®-400
Figure 2 6: Retrospective Study of MRI in Pediatric Patients
Figure 2 7: A Pilot Trial Using BR55 Ultrasound Contrast Agent
Figure 2 8: Crossover Comparison of MultiHance and Dotarem (BENEFIT)
Figure 2 9: Multidetector Computed Tomography (MDCT) Tailored Protocol
Figure 2 10: Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body
Figure 2 11: Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body
Figure 2 12: CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol (CTP)
Figure 2 13: Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis
Figure 2 14: Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors
Figure 2 15: Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors
Figure 2 16: Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol (LLI-MSE)
Figure 2 17: A Multi-Reader Multi-Case Pivotal Trial
Figure 2 18: Pilot Mammography Reader Study
Figure 2 19: Acquisition of Breast Mammography Images
Figure 2 20: Study Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI)
Figure 2 21: Pilot 3D Mammography Reader Study to Assess Breast Cancer Detection
Figure 2 22: Pilot Study Comparing Diagnostic Imaging Versus Tomosynthesis in Detection of Hip, Wrist or Tibia Injury (TOMO)
Figure 2 23: Collection of FUJIFILM's 3Dimensional Mammograms (3DM)
Figure 2 24: International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients
Figure 2 25: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase2)
Figure 2 26: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis
Figure 2 27: Non-invasive Quantification of Liver Iron With MRI
Figure 2 28: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis
Figure 2 29: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis
Figure 2 30: Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit (Firefly)
Figure 2 31: Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy
Figure 2 32: Clinical Evaluation of an Integrated PET/MRI System (PET/MR_ZURICH)
Figure 2 33: Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening
Figure 2 34: Development of an Integrated PET/MR System, Accessories and Components
Figure 2 35: Comparison of 18F FDG PET/CT TO PET MRI (PET/MR US)
Figure 2 36: Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images
Figure 2 37: Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView
Figure 2 38: Clinical Evaluation for GE CT System
Figure 2 39: A Case Collection Study for Digital Breast Tomosynthesis (DBT)
Figure 2 40: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection
Figure 2 41: Magnetic Resonance Imaging Using Innovative Pulse Sequences
Figure 2 42: MRI Scanning of People With MR Safe Orthopedic Implants That Are Made of Metal (MRI)
Figure 2 43: Contrast Ultrasound Detection of Sentinel Lymph Nodes
Figure 2 44: Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer
Figure 2 45: PET/CT for Staging Rectal Cancer Patients With and Without EMVI-MR
Figure 2 46: Contrast Enhanced Spectral Mammography (CESM) Study (CONTEND)
Figure 2 47: Assessment of Automated Breast Ultrasound
Figure 2 48: Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging
Figure 2 49: How Beta-amyloid Imagining Influences Clinician Diagnosis and Management
Figure 2 50: Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas
Figure 2 51: Use of MIBG Scan Images in PVC Ablations (PVC-MIBG)
Figure 2 52: Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI
Figure 2 53: Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques
Figure 2 54: A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide
Figure 2 55: 123I-mIBG SPECT Imaging
Figure 2 56: Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI (Flucipro)
Figure 2 57: FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
Figure 2 58: The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease
Figure 2 59: Imaging Biomarkers of Delayed Sequelae in Trauma Brain Injury
Figure 2 60: Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization (In-Live)
Figure 2 61: P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Figure 2 62: Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI
Figure 2 63: Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI
Figure 2 64: Evaluation of Gadoterate in Patients With Decreased Kidney Function
Figure 2 65: Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Figure 2 66: Hepatic Xenetix-CT Perfusion
Figure 2 67: Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis
Figure 2 68: Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography
Figure 2 69: Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Figure 2 70: Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI
Figure 2 71: Virtual Path Planning for Image-guided Needle Interventions
Figure 2 72: Applications of Dual-Energy Computed Tomography
Figure 2 73: X-ray Dose Reduction Study for Cardiac Angiography and Intervention
Figure 2 74: X-ray Dose Reduction Study for Endovascular Interventional Radiology
Figure 2 75: X-ray Dose Reduction in Electrophysiology
Figure 2 76: Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound
Figure 2 77: MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer
Figure 2 78: Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids (SOFIA)
Figure 2 79: Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter
Figure 2 80: Percutaneous Closure of Atrial Septal Defects in Children
Figure 2 81: Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy
Figure 2 82: Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking
Figure 2 83: Chest Ultrasound of ER Patients With Cough or SOB
Figure 2 84: The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer
Figure 2 85: Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation
Figure 2 86: MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
Figure 2 87: Evaluation of Diagnostic Accuracy of Contrast Enhanced Dual Energy Mammography Imaging
Figure 2 88: Evaluation of an Innovative Medical Device Supporting Orthopedic Surgical Interventions (VIPS)
Figure 2 89: PET/MRI in Patients With Suspected Prostate Cancer
Figure 2 90: Perfusion CT as a Predictor for Response to Antiangiogenic Therapy
Figure 2 91: Verification of the Quantitative Accuracy of the PET/CT System Imaging Chain
Figure 2 92: General Investigative MRI Protocol
Figure 3 1: Nuclear Medicine Imaging Market by Segment, U.S., 2012 – 2022 (US$M)
Figure 3 2: PET/CT Market, U.S., 2012 – 2022
Figure 3 3: SPECT Market, U.S., 2012 – 2022
Figure 3 4: SPECT/CT Market, U.S., 2012 – 2022
Figure 3 5: Drivers and Limiters, Nuclear Medicine Imaging Market, U.S., 2015
Figure 3 6: Leading Competitors, Nuclear Medicine Imaging Market, U.S., 2015
Figure 5 1: Press Release Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report